A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of PEX010 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.
Phase: PHASE2 | Sponsor: Psyence Australia Pty Ltd | Compound: Psilocybin
- Status
- recruiting
- Institution
- Psyence Australia Pty Ltd
- Start date
- 2025-09-15
- End date
- 2026-08-21
- Registry ID
- NCT07072728
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.